A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7 | Synapse
March 3, 2026
A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7
Key Points
Ivonescimab shows promise as a first-line treatment for metastatic lung cancer, specifically with high PD-L1 expression.
The study demonstrates a comparative analysis with pembrolizumab, reflecting significant tumor response rates.
Randomized phase III study highlights crucial insights into immunotherapy effectiveness in metastatic lung cancer.
Results may indicate new options for treatment in patients with high tumor PD-L1 expression, enhancing care strategies.